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Abstract
Standard analyses applied to genome-wide association data are well designed to detect additive effects of
moderate strength. However, the power for standard genome-wide association study (GWAS) analyses to
identify effects from recessive diplotypes is not typically high. We proposed and conducted a gene-based
compound heterozygosity test to reveal additional genes underlying complex diseases. With this approach
applied to iron overload, a strong association signal was identified between the fibroblast growth factor–

encoding gene, FGF6, and hemochromatosis in the central Wisconsin population. Functional validation showed
that fibroblast growth factor 6 protein (FGF-6) regulates iron homeostasis and induces transcriptional regulation
of hepcidin. Moreover, specific identified FGF6variants differentially impact iron metabolism. In addition, FGF6
downregulation correlated with iron-metabolism dysfunction in systemic sclerosis and cancer cells. Using the
recessive diplotype approach revealed a novel susceptibility hemochromatosis gene and has extended our
understanding of the mechanisms involved in iron metabolism.

Introduction
Genome-wide association studies (GWASs) are well designed to detect additive effects of modest effect sizes.
We hypothesized that gene-based tests sensitive to recessive diplotypes, including recessive single-site effects
and compound heterozygosity, may reveal additional genes underlying complex diseases. Carrying variants
conferring a compromised function on both homologous chromosomes is likely to impact molecular
physiological states. Deep-sequencing studies have conclusively shown a vast reservoir of rare variants
segregating in human populations.1 Rare variants in functional categories (eg, missense, regulatory motifs) may
generate pathogenic effects through recessively acting diplotypes, and such effects are apt to remain concealed
from standard GWAS analyses. Simple power calculations show that recessive diplotype inheritance produces
signals that are difficult for standard GWAS methods to discover (supplemental Figure 1, available on
the Blood Web site). Compound heterozygosity disease models also enjoy a high degree of biological plausibility,
particularly if the alleles confer compromised protein function.2-5 Recessive diplotype modes of inheritance are
well established in Mendelian diseases, such as cystic fibrosis,6 mevalonic aciduria,7 β-thalassemia,8and
Niemann-Pick disease.9 Although not systematically examined in population-based studies, there is a sizable
repository of genes underlying complex diseases with recessive, loss-of-function effects.10-14 Hence, we posited
that an exome-wide, gene-based screen of recessive diplotypes using putative functional variants in both
oligogenic and complex diseases may expand our knowledge of disease genes.
Iron-metabolism disorders, including adult hereditary hemochromatosis, collectively are common conditions
with considerable public health implications.15,16Importantly, the hepatic hormone hepcidin is a key regulator
of iron homeostasis by controlling iron flux from enterocytes and macrophages to plasma through degradation
of the cellular iron exporter ferroportin (SLC40A1). Within cells, ferritin is the iron-storage protein that can be
used for indirect iron quantification. To investigate the inheritance of hemochromatosis, several segregation
analyses were initially conducted, concluding that a recessive mode of inheritance is highly
plausible.17,18 Several human studies have investigated the genetics of iron overload, revealing several critically
important genes. Notably, HFE, encoding the membrane-bound hereditary hemochromatosis protein, was
mapped 2 decades ago through family-based linkage19-22 and association approaches.23,24 Additional studies
have definitively placed the missense polymorphism C282Y (rs1800562) in HFE as the major susceptibility factor
in adult-onset, type 1 hereditary hemochromatosis.25,26 Additional genes have been identified through
pathway-based genetic association studies and GWASs, including BMP2, BMP4, HJV, TF, TMPRSS6, NAT2, FADS2,
and TFR2.27-29

Methods
Central Wisconsin hemochromatosis sample set

The homogenous population in rural central Wisconsin is the source population for the Personalized Medicine
Research Project (PMRP), a biobank linked to electronic health records (EHRs) housed by the Marshfield Clinic
Research Institute.30 Samples from over 20 000 individuals comprise the PMRP. The study was conducted in
accordance with the Declaration of Helsinki. All samples were collected following written informed consent. All
investigators using the PMRP samples had obtained Research Ethics and Compliance Training certification

through the Collaborative Institutional Training Initiative (CITI) program. The study protocol was reviewed and
approved by the Marshfield Clinic Institutional Review Board (details in “Acknowledgments”). The Central
Wisconsin population is largely stationary and primarily derived from Bavarian migrants in the late 1800s. The
population carries high utility for disease gene mapping through reduction in confounding by population
stratification and lower expected levels of allelic and locus heterogeneity. Additionally, environmental exposures
are thought to be relatively uniform across this population. For these reasons, the PMRP has been effectively
used in numerous human genetics studies.31-34 PMRP DNA samples were collected and stored ∼14 years ago
and all individuals have longitudinal EHR information housed at the Marshfield Clinic, averaging >30 years. The
EHR is composed of International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes, laboratory
test results, clinical procedure data, prescription information, and physician notes. Hemochromatosis cases and
controls were selected from the PMRP population. Hemochromatosis cases were selected on the basis of the
percent transferrin saturation laboratory values (the ratio of serum iron to transferrin iron-binding capacity)
exceeding 48% and having 2 or more instances of ICD-9 codes indicating the diagnosis of hemochromatosis:
275.0 (iron metabolism disorder, excluding anemia), 275.01 (hereditary hemochromatosis), 275.03 (unspecified
hemochromatosis), and/or 275.09 (other iron-metabolism disorders). To reduce confounding by population
stratification, a principal components analysis on the exome-genotyping data was implemented using all
samples, blinded to disease status. Individuals considered genetic background outliers (>3 standard deviations
from the centroid of the first 2 principal components) were excluded from the study. Following the removal of
outliers, the resulting set of individuals was highly homogeneous based on the first 3 principal components.
Exhaustive pairwise kinship coefficients were calculated and 1 individual from pairs of individuals exhibiting
third-degree or closer relatedness were removed. Of the ∼10 000 individuals previously subjected to the exomegenotyping array and quality control procedures, the phenotype algorithm identified 18 individuals who were
selected as hemochromatosis cases. Controls (n = 6896) were individuals without abnormal saturation values
and without any instances of hemochromatosis ICD-9 codes.

Genotyping

Of the full PMRP cohort, ∼10 000 DNAs were interrogated by high-density genotyping on the Illumina
HumanCoreExome beadchip. This exome array of >500 000 markers has ancestry informative markers, a panel
of identity-by-descent single nucleotide polymorphisms (SNPs), coverage of markers found to be genome-wide
significant in GWASs, and excellent coverage of exonic variants. The version of the beadchip was designed and
used in the AMD Consortium.34 Rare variants (<1% frequency) represented 47.8% of the markers, moderately
common variants (1% to 10% frequency) were 8.1% of the variants, and 44.1% of the variants interrogated were
common alleles (>10% frequency). The genotyping quality control measures were previously described (call
rates for each variant or individual >0.985).34 Variants exhibiting departure from Hardy-Weinberg equilibrium
(P < 1 × 10−6) were excluded from subsequent analyses. Additional recent studies have used data generated
from this genotyping to discover susceptibility genes for common diseases.35 Following quality control
procedures, 413 701 variants remained for analysis. The site frequency spectrum of the resulting variants is
displayed in supplemental Figure 2 and supplemental Table 1.

Haplotype phasing

In general, gametic phasing is necessary to directly determine compound heterozygous individuals at a
particular gene. Using all 10 000 exome-genotyped samples from the PMRP, the software package Beagle was
applied to infer phased haplotypes from unphased genotype data using a localized haplotype-cluster model
algorithm.36 The calculations were performed on a high-performance computing cluster housed at the
Marshfield Clinic. As the subsequent analyses were gene-based and the genotyping data were concentrated on
exonic variants, each gene in the exome was phased separately using this approach. Although rare variants can
present difficulties in phasing, the use of a large sample size from a highly homogeneous population aids in

mitigating the error rate. Notably, Beagle has been shown to have error rates in phasing between 0.77% to
0.94% for medium (n = 1000) to large (n = 5000) sample sizes using a 500K GWAS array.36 Recently, the switch
error rate was calculated for the Beagle applied to 2 sequencing data sets. Beagle attained a switch error rate of
1.525% and 0.488% for the 1000 Genomes Project and Haplotype Reference Consortium, respectively.37

Determination of putative functional variants

Following the phasing of the genotype data, putative functional variants were identified. The putative functional
variants included in the analyses satisfied the quality control criteria as described previously.34 Markers used in
the analyses were either GWAS-significant as of June 2015 and/or annotated as missense, nonsense, 3′
untranslated region, 5′ untranslated region, or occurring within a splice site region. Additionally, on the resulting
set of variants, annotation was performed using the ANNOVAR software.38 Only variants that were also
annotated as pathogenic by at least 2 ANNOVAR predictions were included in the scan. Following filtering for
putative functional variants, 129 556 SNPs remained for use in our gene-based recessive diplotypes scan. The
putative functional variants of FGF6 are shown in supplemental Table 2.

Statistical tests of recessive diplotypes

At each gene, individuals were classified as having a recessive diplotype configuration if they carried at least 1
putative functional allele on each homolog (PF). Individuals carrying at least 1 homolog free from putative
functional alleles were deemed as having a wild type (WT) diplotype (W). The total number of case/control
individuals carrying a recessive diplotype was denoted by PFcs and PFct, respectively. Similarly, the total number
of case/control individuals carrying a WT diplotype was denoted by Wcs and Wct, respectively. Following the
determination of these counts, a Fisher exact test was applied. As the hypergeometric null density holds for all
sample sizes, the Fisher exact test is robust to imbalance between case and control sample sizes. Simulations
have recapitulated this finding showing that the Fisher exact test does not inflate type I error rates under
unbalanced designs.39Individuals carrying 1 or more homozygous genotype(s) at a single site for a putative
functional allele were included in the PF category. Genes without any high-quality, putative functional alleles
across all samples were removed from the analyses. Across all genes with analyzable data, a conservative
experiment-wise multiplicity correction was calculated using 15 900 gene-based tests. To compare the recessive
diplotype analysis procedure to a standard rare variant gene-based test, the RVTESTS software,40 which
implements the sequence kernel association test, was also applied to the genotype data.41 Additionally, to
investigate the sex-specific effects, the Haldane odds ratio (OR) was calculated separately for female and male
strata. Lastly, the Mantel-Haenszel test of homogeneity was calculated to determine the level of statistical
evidence for sex-specific differences in effects.42

Power calculations

To explore the efficacy of the proposed approach, we performed analytic power calculations under the
alternative model of compound heterozygosity/recessive inheritance of disease at 2 sites, each segregating 2
alleles. By doing so, we sought to compare the power of a standard GWAS analysis (Armitage trend test) to a
log-likelihood ratio G test.42 Supplemental Figure 1 shows the power of each of these tests across different sets
of penetrances and haplotype frequencies. To consolidate the different sets of haplotype frequencies, the
results are plotted as a function of linkage disequilibrium between the 2 sites. The power of the G test for
recessive diplotypes exceeded the power for the Armitage trend test across virtually all of the parameter space.
Additional work in this area was recently performed by Sanjak et al showing similar results.43

Comparative genomic analysis and protein-protein interaction inference

Amino acid sequencing of the core iron-metabolism genes were collected, including transferrin receptor 1
(TFRC), FTH1, IREB1, SKP1, SKP1, ACO1, TFR2, TF, HMOX1, ACO2, HAMP, FGF6, and FGFR1. The alignments were

derived from National Center for Biotechnology Information (NCBI) BLASTn database. Phylogeny for different
genes were compared, showing the earliest evolutionary time point; then, occurrence for each gene was
mapped to the phylogenetic tree.44 Protein-protein interaction network inference was conducted to fibroblast
growth factor 6 protein (FGF-6) and main iron-metabolism proteins. The finial network was tuned after
removing nonnecessary nodes between FGF-6 and key iron molecules including hereditary hemochromatosis
protein (HFE) and SLC40A1.

Cell culture, reagents, and protein treatment

Colon cancer cell lines (HCT8 and HCT116), a kidney cancer cell line (786-O), a liver cancer cell line (HepG2), and
a fibroblast cell line (HFF-1) were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS) at 37°C in a 5% CO2 humidified incubator. To investigate the change in iron uptake
under different protein treatments or plasmid transfection, the ferric ammonium citrate (FAC) cell culture
method was used. Cells were cultured in normal DMEM and FBS medium with the presence of 10 μM FAC and
500 μM ascorbate for 48 hours during detection of cellular iron concentration. Cells cultured in normal medium
exhibited very low iron concentrations. Total intracellular iron concentration in cells cultured with FAC for 48
hours was dramatically increased over cells cultured in normal medium. Recombinant human FGF-6 protein
(active) and anti-ferritin were purchased from Abcam, Flag tag antibody was purchased from Proteintech Group,
and anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Shanghai Yeasen
Biotechnology. FAC (1 mM) and ascorbate (50 mM) were dissolved in distilled water. NaOH, HCl, KMnO4,
ferrozine, neocuproine, ammonium acetate, ascorbic acid, and FeCl3 were purchased from Beijing Oka Biological
Technology. Plasmid with raw FGF6 sequence was purchased from PPL-Shanghai Co, Ltd, which was constructed
in an N-terminal p3XFLAG-CMV vector, whereas 3 different FGF6 mutations (E127X, D174V, R188Q) were
synthesized with overlapping polymerase chain reaction (PCR).

Quantification of iron content by ferrozine assay

Total intracellular iron content was measured by the ferrozine assay.45 Cells were cultured in 12- or 24-well
plate for 48 hours and washed 3 times with cold phosphate-buffered saline (PBS). After being lysed for 2 hours
with 50 mM NaOH, 100 μL of cell lysates was mixed with 10 mM HCl, and 100 μL of the iron-releasing reagent (a
freshly mixed solution of equal volumes of 1.4 M HCl and 4.5% [wt/vol] KMnO4 in H2O). The mixtures were
incubated for 2 hours and 30 μL of iron-detection reagent (6.5 mM ferrozine, 6.5 mM neocuproine, 2.5 M
ammonium acetate, and 1 M ascorbic acid) was added; after 30-minute incubation, 280 μL of solution was
added to a 96-well plate and read 550 nm on a microplate reader. In addition, FeCl3 (0-100 μM) was used as iron
standards and protein quantification was determined by a Lowry protein assay.

Western blot

Cell lysates were harvested when incubated with iron for 48 hours, then equal amounts of protein from every
sample were subjected to 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and then transferred
to polyvinylidene difluoride membranes. After blocking with 5% bovine serum albumin (BSA), the membranes
were incubated with GAPDH (1:10000), ferritin (1:1000), and Flag (1:2000) at 4°C overnight. Then, membranes
were washed 3 times with Tris-buffered saline plus polysorbate 20, incubated with anti-rabbit or anti-mouse
secondary antibody. The bands were visualized using Image QuantTL software.

Perls staining

Cells were washed with PBS 3 times, fixed with 4% glutaraldehyde for 10 minutes, and incubated at 37°C for 60
minutes with 2 mL of Prussian blue solution comprising equal volumes of 2% hydrochloric acid aqueous solution
and 2% potassium ferrocyanide (II) trihydrate. After the cells were stained with 0.5% neutral red for 3 minutes,

iron staining was visualized by Nikon microscope. Iron-positive high positive staining cells divided by total cell
number was used to evaluate the iron-deposition levels.

RT-PCR and quantitative RT-PCR analysis

Total RNA was extracted from the cells using TRIzol (Invitrogen). One microgram of total RNA was subjected to
complementary DNA synthesis using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems)
according to the manufacturer’s instructions. The specific primers for each gene were designed using Primer 5
and synthesized by Generay Biotech Co, Ltd. The reverse transcription polymerase chain reaction (RT-PCR)
amplification was conducted using a SYBR Green I PCR kit (TaKaRa) according to the manufacturer’s instructions.
The reaction was carried out on an ABI Prism 7900 Detector System (Applied Biosystems). RT-PCR conditions
were 95°C for 3 minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 40 seconds; the conditions for
obtaining the dissociation curve were 95°C for 15 seconds, 60°C for 15 seconds, 95°C for 15 seconds. The data
obtained from the assays were analyzed with SDS 2.3 software (Applied Biosystems). For each sample, the
relative gene expression was calculated using a relative ratio to GAPDH. RT-PCR primers can be found in the
supplemental Table 3.

Immunohistochemical staining of FGF-6

The primary antibody used was anti-FGF-6 (1:200; BBI) and anti-ferritin (1:100; abcam). Liver and skin tissues
from 4 liver cancer patients and 6 systemic sclerosis (SSc) patients, respectively, and normal controls were
formalin-fixed and paraffin-embedded. Sections were deparaffinized and incubated with 5% BSA for 60 minutes.
Cells positive for FGF-6 were detected by incubation with the primary antibody for 2 hours at room temperature
followed by incubation with 3% hydrogen peroxide for 10 minutes. Rabbit anti-rabbit immunoglobulin G labeled
with horseradish peroxidase was used as secondary antibody. The expression of FGF-6 or ferritin was visualized
with 3,3-diaminobenzidinetetrahydrochloride (DAB-4HCl). The expression of FGF-6 in SSc and tumor tissues was
quantitated by the average optical density (AOD) of the positive signal in each sample using NIH ImageJ software
(Windows and Java-1.8.0).

Results
Gene-based compound heterozygosity scan identifies a novel hemochromatosissusceptibility gene

To discover novel iron-overload–predisposing genes, we conducted a gene-based scan for recessive diplotypes
composed of putative functional alleles across the exome using biobanked samples linked to electronic medical
records obtained from a rural, genetically homogeneous population in central Wisconsin. Of the 10 000 samples
evaluated, our transferrin saturation and diagnostic code-based phenotype algorithm identified 18 case
individuals and 6896 controls. We estimated gametic phase on all individuals and restricted our analyses of
diplotypes to putative functional variants. Our recessive diplotype scan identified 2 exome-wide significant
genes (Figure 1; Table 1; supplemental Figure 3), HFE (P = 1.29 × 10−8; OR = 28.7) and FGF6 (P = 1.99 × 10−6; OR =
22.8). For comparison, the SKAT/rvtest procedure on the FGF6 genotype data yielded an asymptotic P = 3.86 ×
10−5 and permuted P = 1.0 × 10−4. Notably, the recessive diplotype scan result exceeded exome-wide
significance, whereas the rare variant test did not. Additionally, there was no statistical evidence of effect
differences between females and males for the FGF6data (Mantel-Haenszel test of homogeneity P = .728). These
results motivated our investigation of FGF-6 function and the impact of specific FGF6 variants on iron
metabolism.

Figure 1. Manhattan plot of the gene-based recessive diplotype association results. The association P-value
testing hemochromatosis association for each gene (−log10 p plotted on the ordinate) on different chromosomes
is shown in alternating navy blue and yellow along the abscissa, with the experiment-wise significance level for
the gene-based analyses across the exome (experiment-wise α = 3.14 × 10−6) depicted in red.
Table 1. Significant genes identified by recessive diplotype scanning
Chromosome
Gene
P
OR
SNPs
Case+
Case−
Control+
chr6
HFE
1.29 × 10−8
28.6
14
8
10
189
−6
chr12
FGF6
1.99 × 10
22.8
10
6
12
153
chr21
KRTAP15-1
7.55 × 10−5
6.78
5
11
7
1271
−4
chr20
XKR7
1.18 × 10
43.6
7
3
15
35
chr20
CABLES2
1.28 × 10−4
42.4
7
3
15
36
−4
chr22
THOC5
1.38 × 10
6.24
9
13
5
1945
The 6 most significant genes identified in the recessive diplotype scan are displayed. P values are from a 2-tailed
Fisher exact test.

Case+, number of iron-overload case individuals carrying recessive diplotypes with putative functional alleles;
Case−, number of cases carrying at least 1 homolog at the gene without a putative functional allele; Control+,
number of control individuals carrying recessive diplotypes with putative functional alleles; Control−, number of
controls carrying at least 1 homolog at the gene without a putative functional allele; OR, Haldane odds ratio;
SNP, number of genotyped variants per gene that were polymorphic in the samples studied.

Protein-protein interaction indicates FGF-6 is involved in iron-metabolism network

To explore the involvement of FGF6 in iron metabolism, we found evidence for FGF-6 interactions with FGFR1,
MAPK1/3, INS, FN1, and involvement in the iron-metabolism subnetwork involving transferrin (TF), HFE,
hepcidin antimicrobial peptide (HAMP), and SLC40A1 (supplemental Figure 4) by investigating FGF-6 proteinprotein interactions. FGF-6, also known as heparin secretory-transforming protein 2 or heparin-binding growth
factor 6, has multiple heparin-binding sites (HBSs). Three known nonsynonymous variants located in the HBSs
(R188Q) or flanking sites (D174V and E172X) were speculated to be important for FGF-6 function. Furthermore,
D174V and E172X are located in the regions between FGFR-binding region (FGFR-BR-3) and HBS-1 (Figure 2).
Hence, we studied these 3 variants in functional studies to further investigate the involvement of FGF-6 in iron
metabolism.

Contro
6707
6743
5625
6861
6860
4951

Figure 2. Protein sequence alignment for FGF-4, FGF-5, and FGF-6 with heparin and FGFR-binding
domains.Protein domains summarized from a previous FGF-6 functional study.58 Alignment and heparin and
FGFR-binding sites/regions (HBS and FGFR-BR, respectively) are shown for FGF-4, FGF-5, and FGF-6 proteins.

FGF-6 modulation of hepcidin expression and iron uptake

To investigate the potential mechanism linking FGF-6 to iron metabolism, the effects of FGF6 on iron uptake and
the expression of iron-metabolism genes in HepG2, HCT8, HCT116, 786-O, and HFF1 cells were evaluated. Using
cultured cells and a ferrozine assay to detect iron, total intracellular iron concentration was significantly
decreased in HepG2, 786-O, HCT8, HCT116, and HFF-1 cells when treating with active FGF-6 protein in a dosedependent manner (Figure 3; supplemental Figure 5). Testing the effect of FGF6 on the expression of a set of
genes involved in iron metabolism (HAMP, HDAC2, HMOX1, TFRC, and HEPH), HepG2 cells were subjected to
treatment from control or FGF-6 protein and FGF6messenger RNA (mRNA) or control and mRNA expression
relative to GAPDH was measured in the 5 iron-metabolism genes. RT-PCR analysis revealed
that HAMP and HDAC2 mRNA levels were significantly increased after the FGF-6 active protein introduction in
HepG2 cells compared with treatment with PBS as control (Figure 4A). FGF6 plasmid transfection significantly
increased HAMP, HDAC2, and HMOX1levels, whereas TFRC levels significantly decreased in HepG2 compared
with a vector without FGF6 (Figure 4B). HEPH expression did not change with either FGF6 plasmid or FGF-6
protein, suggesting that the effect of FGF-6 may be independent of HEPH(Figure 4A-B).

Figure 3. FGF-6 active protein dosage effect on intracellular iron concentration. A ferrozine assay was applied
for the evaluation of total cell iron content in HepG2 (human liver hepatocellular carcinoma cell line), 786-O
(human kidney adenocarcinoma cell line), HCT-8 (human ileocecal colorectal adenocarcinoma cell line), HCT116
(human colon carcinoma cell line), and HFF-1 (human skin fibroblast cell line) with 10 μM FAC and 500 μM
ascorbate in cell culture media, respectively, with different concentrations of FGF-6 active protein (0 ng/mL, 2.5
ng/mL, 25 ng/mL, and 250 ng/mL). Control group was treated with ascorbate alone. After 48-hour incubation,

cells were lysed and iron contents were determined with the ferrozine assay. (A) Total iron content in HepG2
cells with increasing FGF-6 protein concentration. (B) Total iron content in 786-O cells with increasing FGF-6
protein concentration. (C) Total iron content in HCT-8 cells with increasing FGF-6 protein concentration. (D)
Total iron content in HCT-116 cells with increasing FGF-6 protein concentration. *P< .05, **P < .01, ***P < .001.

Figure 4. The effect of FGF6 nonsynonymous variants on hepcidin expression and intracellular iron
concentration. (A) The effect of FGF-6 active protein treatment on mRNA expression of several iron metabolism
genes in HepG2 liver hepatocellular carcinoma cell culture media compared with control. Protein concentration
was 250 ng/mL and the incubation time was 24 hours with 10 μM FAC and 500 μM ascorbate in the cell culture
media. HAMP encodes for hepcidin. HDAC2 encodes for histone deacetylase 2. HMOX1 encodes for heme
oxygenase 1. TFRC encodes for transferrin receptor 1 and HEPH encodes hephaestin. mRNA expression was
quantified relative to GAPDH expression. Treatment with PBS served as control. A Student t test was used test
for pairwise differences between sets of observations. *P < .05. Results are the mean ± standard deviation (SD)
of 3 observations in a single experiment. (B) Iron-metabolism gene expression changes with FGF6 mRNA
transfection in the HepG2 cell culture media after 24 hours. Vector without FGF6 served as control. A
Student t test was used to test for pairwise differences between sets of observations. *P < .05. Results are the
mean ± SD of 3 observations in a single experiment. (C-D) Iron-metabolism gene-expression changes after the
transfection by FGF6 mRNA into various cell types with WT and the identified variants E172X (M1), D174V (M2),
and R188Q (M3). Cell lines: HepG2 are liver hepatocellular carcinoma cells, HCT116 are ileocecal colorectal
adenocarcinoma cells, and HFF-1 are human normal skin fibroblasts. A Student ttest was used to test for

pairwise differences between sets of observations. *P < .05. Results are the mean ± SD of 3 observations in a
single experiment. (E-F) Total intracellular iron-concentration changes after the transfection with FGF6 mRNA
into 3 cell types with WT and the identified M1, M2, and M3 variants in the presence of FAC for 48 hours. A
Student t test was used to test for pairwise differences between sets of observations. *P < .05; **P < .01. Results
are the mean ± SD of 3 observations in a single experiment. (G-H) Ferritin protein level changes after the
transfection by FGF6mRNA into the 3 cell types with WT and the identified M1, M2, and M3 variants in the
presence of FAC for 48 hours. A Student t test was used to test for pairwise differences between sets of
observations. *P < .05. Results are the mean ± SD of 3 observations in a single experiment.

Evaluation of FGF6 variants on HAMP expression and iron concentration compared with
WT FGF6

To investigate the effects of the FGF6 alleles on FGF-6 function, we transfected plasmids carrying either the
WT FGF6 or variant FGF6 with each of the 3 point mutations described in Figure 2 (supplemental Figure 6). The
M1 (E172X) and M3 (R188Q) variants exhibited a significant downregulation of HAMP mRNA compared with WT
in HepG2 cells (Figure 4C), HCT-116 cells (Figure 4D), 786-O (supplemental Figure 7), A498 (supplemental Figure
7), but not HCT-8 cells (supplemental Figure 7). Evaluating the effect of M2 (D174V) on HAMP expression
compared with WT only yielded a significant reduction in HepG2 (Figure 4C), but not in any of the other cell lines
(Figure 4D; supplemental Figure 7). Furthermore, we noted HAMP mRNA levels in M1 and M3 transfections
were comparable to control levels, which illustrated a strong attenuation of FGF-6 function for M1 and M3
variants (Figure 4C-D; supplemental Figure 7). Examining the impact of specific variants on intracellular iron
concentration in HepG2 and HCT-116 cells, M1 and M3 produced significantly elevated iron deposition (Figure
4E-F; supplemental Figure 8) and ferritin expression (Figure 4G-H; supplemental Figure 8), indicating a deficiency
in M1/M3 FGF6-mediated iron homeostasis. In addition, the intracellular iron-accumulation pattern was
confirmed by immunohistochemistry (IHC) using Perls stain (supplemental Figure 9). In contrast, M2 did not
produce a significant departure from WT in iron concentration and ferritin expression in HepG2 and HCT-116
(Figure 4). Furthermore, TFRC expression was significantly upregulated in the presence of M3 compared with
WT (Figure 4C). The functions mentioned were also validated in HFF-1 (supplemental Figure 8).

Altered FGF6 gene expression in SSc and cancer

We hypothesized that FGF-6 might be involved in human autoimmune diseases and cancers because abnormal
iron metabolism has been reported in numerous studies.46-50 More specifically, decreased hepcidin has been
implicated in the anemia of chronic disease, which frequently accompanies these systemic inflammatory states.
To explore the relationship between FGF6 expression and iron deposition in autoimmune
tissues, FGF6 expression and iron deposition in the skin lesions from SSc patients and healthy controls were
examined. We found significantly decreased FGF-6 protein by immunohistochemistry assay (Figure 5A) and
elevated iron deposition in SSc skin tissue by ferrozine assay (Figure 5B), especially in the epidermis. Increased
iron deposition was confirmed by Perls stain in SSc skin tissues (supplemental Figure 10A). We also investigated
the relationship between FGF6 protein expression with iron deposition in liver cancer tissues. We found that
FGF-6 was significantly decreased in nonmetastatic cancer lesion tissues (Figure 5C) and the increased iron
deposition (Figure 5D; supplemental Figure 10B). However, increased FGF-6 expression was observed in
metastatic liver carcinoma tissue (supplemental Figure 11), suggesting that FGF-6 plays different roles in
oncogenesis and metastasis, analogous to transforming growth factor β.51,52

Figure 5. Perls stain and ferritin expression. (A) FGF-6 protein level was evaluated by IHC assay (IHC) in skin
tissues from SSc patients and healthy controls (Normal). Staining was visualized by Nikon microscopy; original
magnification ×200. A Student t test was used to test for pairwise differences between AOD values between SSc
and normal observations. The ratio of positive stain areas to the total area was used to evaluate protein levels.
AODs were quantified by ImageJ software. **P < .01. (B) IHC with Perls Prussian Blue stain for ferritin protein
was applied to evaluate the iron deposition in SSc skin tissues and healthy skin tissue. AOD values were
quantified by ImageJ software. Staining was visualized by Nikon microscopy; original magnification ×200. **P <
.01. (C) IHC of FGF-6 protein in liver cancer tissue and control tissue. AODs were quantified by ImageJ software.
Staining was visualized by Nikon microscopy; original magnification ×200. *P < .05. (D) IHC of ferritin protein
using Perls Prussian Blue stain in liver cancer tissue and control tissue. AODs were quantified by ImageJ
software. Staining was visualized by Nikon microscopy; original magnification ×200. *P < .05.

Discussion
Iron homeostasis results from a combination of pathways and 4 main cell types: enterocyte, hepatocyte,
macrophage, and erythroblast. The epidermal growth factor/epidermal growth factor receptor signaling
pathway, heme production, STAT signaling, cyclic adenosine monophosphate signaling, ferritin storage, and
bone morphogenetic protein–SMAD signaling are all involved in iron regulation. We conducted an exome-wide,
gene-based recessive diplotype scan using putative functional variants to reveal additional genes underlying
hemochromatosis susceptibility, an approach that can be widely applied to investigate complex disease
susceptibility generated by compound heterozygosity and recessive single-site effects using existing exome-wide
association genotype and sequencing data. Although the case sample size was very small, this novel scan
identified FGF6 as being significantly associated with hemochromatosis following correction for multiple
testing. FGF6 belongs to the paracrine FGF gene family and is largely expressed in skeletal muscle, which plays
an important role in iron metabolism as it contains 10% to 15% of iron stores. We conducted the evolutionary
analysis of FGF6and known iron-metabolism genes including FGFR1, TFRC, FTH1, IREB1, TF, HMOX1, ACO2,
and HAMP (encoding hepcidin). The appearance of iron-metabolism genes can be separated into 2
stages. TF and HMOX1, which are found in animals from Caenorhabditis elegans to Homo sapiens, indicate an
origin in early Bilateria evolution (∼635 million years ago [Mya]). FGF6, FGFR1, ACO2, and HAMP can be found
from Danio rerio to H sapiens, but are not present in C elegans and Drosophila, indicating emergence in early
Vertebrata (∼485 Mya). The coappearance of these genes suggests possible coregulatory functions
(supplemental Figure 4A). Functional experiments demonstrated that FGF-6 strongly impacted hepcidin
expression, thereby playing a role in regulation of iron homeostasis. These results suggest FGF-6 mediates its
effect on iron metabolism via hepcidin. The induction of hepcidin expression by FGF-6 leads to degradation of
ferroportin through binding and internalization of ferroportin by hepcidin as shown in Figure 6. We additionally
found that 3 FGF6 nonsynonymous variants increased intracellular iron concentrations and reduced hepcidin
levels compared with WT FGF6, indicating loss of function. Interestingly, a genome-wide RNA interference–
profiling study reported that knockdown of FGF6 increased transferrin-mediated endocytosis.53Rs12368351, ∼8
kb downstream of FGF6, has been associated with phosphorus levels54; and 2 SNPs, rs140668749 and
rs10849061, within 20 kb downstream of FGF6, are associated with migraine.55,56 Previous studies have
indicated that iron plays a role in autoimmunity and a study examining pulmonary arterial hypertension in SSc

noted iron deposition in lung elastin fibers and giant cells,57 however, epidermal iron deposition in SSc has not
been previously investigated. We observed that FGF-6 is involved with iron deposition in SSc and liver cancer.
Together, these results demonstrate that FGF receptor (FGFR) signaling through FGF-6 is a critically important
mechanism in iron metabolism.

Figure 6. The proposed mechanism of FGF-6 in the regulation of hepcidin expression and iron
concentrations. Paracrine FGF-6 interacts with FGFR with heparin or heparin sulfate proteoglycan (HPSG) as the
cofactor to initial FGF pathway.59 Activated FGFRs have the ability to phosphorylate specific tyrosine residues
and activate STAT3 pathway.60 Iron overload and inflammation could positively regulate hepcidin by BMP/Smad
pathway61 and inflammatory IL-6/STAT3 pathways.62,63However, loss-of-function FGF6 variants will silence the
FGF6-FGFR pathway, increase free heparin, and reduce expression of hepcidin, thereby decreasing the inhibition
of ferroportin-mediated iron transfer from the intracellular compartment to the blood (ie, increasing plasma
levels of iron). In SSc patients, IL-6 is increased so that hepcidin will be positively regulated which suppresses
iron release to the plasma generating higher iron levels in skin cells.
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